Naturgeschichte und Erwerb von Bioproben für Kinder und Erwachsene mit seltenen soliden Tumoren
Naturgeschichte und Bioprobenerfassungsstudie für Kinder und Erwachsene mit seltenen soliden Tumoren
Background:
Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screening, preventive guidelines, and treatments.
Objective:
To better understand rare cancers and hereditary cancer syndromes.
Eligibility:
People who have a rare tumor, a family history of a rare tumor, a hereditary cancer syndrome, or a mutation that leads to rare tumors.
Design:
Participants will be screened with questions about their medical history and/or that of their family members. They will give a saliva sample.
Participants who have a tumor will have their medical records and tests reviewed. They will answer questions about their wellbeing and needs. They may provide a tumor tissue sample.
Participants may also have:
- Physical exam
- Clinical photography
- Blood, urine, saliva, and stool samples taken
- Consultation with specialists
- A scan that produces a picture of the body. Either one that uses a small amount of radiation, or one that uses a magnetic field.
- Genetic testing/genetic counseling.
Participants will be contacted once a year. They will answer updated questions about their medical and family history.
Participants will be asked to contact the study team if there are changes in their tumors.
Participants may be invited to join focus groups for people with the same diagnosis of rare tumors.
Participants may be invited to participate in other NIH protocols.
****************************************
****************************************
RARE TUMOR LIST:
-
Acinar cell carcinoma of the pancreas
-
Adamantinoma
-
Adenosqaumous carcinoma of the pancreas
-
Adrenocortical carcinoma
-
Alveolar soft part sarcoma
-
Anaplastic Thyroid Cancer
-
Angiosarcoma
-
Atypical Teratoid Rhabdoid Tumor/MRT
-
Carcinoid
-
Carcinoma of Unknown Primary
-
Chondrosarcoma
-
Chondromyxoid fibroma
-
Chordoma
-
Clear cell renal carcinoma
-
Clear Cell Sarcoma
-
Clear cell sarcoma of kidney
-
Conventional chordoma
-
Dedifferentiated chordoma
-
Desmoid
-
Desmoplastic small round cell tumor
-
Epithelioid hemangioendothelioma
-
Esthenioneuroblastoma
-
Ewing Sarcoma
-
Fibrolamellar carcinoma
-
Fusion negative rhabdomyosarcoma
-
Fusion positive renal cell carcinoma
-
Fusion positive rhabdomyosarcoma
-
Gastro-enteropancreatic neuroendocrine tumor
-
Hepatoblastoma
-
Hereditary Diffuse Gastric Cancer
-
Inflammatory myofibroblastic tumor
-
Kaposiform hemangioendothelioma
-
Malignant ectomesenchymal tumor
-
Malignant peripheral nerve sheath tumor
-
Malignant triton tumor
-
Medullary thyroid cancer
-
Mixed acinar adenocarcinoma
-
Mixed acinar neuroendocrine carcinoma
-
Myxoid Liposarcoma
-
Neuroblastoma
-
Neuroendocrine tumors
-
NUT midline carcinoma
-
Osteosarcoma
-
Pancreas ductal adenocarcinoma with squamous features
-
Pancreatic acinar cell carcinoma
-
Papillary renal cell carcinoma
-
Paraganglioma
-
Parosteal Osteosarcoma
-
Periosteal Osteosarcoma
-
Peripheral nerve sheath tumor
-
Peripheral primitive neuroectodermal tumor
-
Pheochromocytoma
-
Pituitary cancer
-
Poorly differentiated chordoma
-
Renal medullary carcinoma
-
Rhabdomyosarcoma
-
Round cell Liposarcoma
-
Schwannoma
-
Sclerosing Epithelioid Fibrosarcoma
-
SDH deficient GIST
-
SMARCB1 deficient tumors
-
SMARCA4 deficient tumors
-
Synovial sarcoma
-
Undifferentiated Sarcoma
****************************************
****************************************
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
Background:
Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgkin lymphoma, and kidney/renal pelvis neoplasms) and will not be studied in this trial. One-quarter of all adults with tumor have a rare tumor diagnosis.
All pediatric tumors meet this definition of rare affecting < 1% individuals younger than 20 years per year in the US.
Notably, there is a group of solid tumors that occur so infrequently in children and adults that little is known about the natural history of these tumors, their clinical behavior, molecular/genetic characteristics, optimal management, and drug response.
The NCI and the NIH Clinical Center infrastructure are uniquely suited to conduct studies of rare tumors. There is a precedent in the NCI when even non-interventional studies or initiatives were paradigm-changing. The NCI neurofibromatosis type 1 natural history study allowed the development of groundbreaking interventional trials in participants with plexiform neurofibromas. The Pediatric and Wild-Type Gastrointestinal Stromal Tumor (GIST) Clinic, which involves intramural and extramural experts, not only provided the background for discovery of the molecular features of a very rare disease such as succinate dehydrogenase deficient GIST, but also was able identify therapeutic strategies for this group of participants (for example, avoidance of unnecessarily aggressive surgery). Similarly, studies in adults at the CCR have tremendously advanced the understanding of rare solid tumors occurring primarily in adults such as thymoma, renal cell cancer, and endocrine tumors.
Systematic and longitudinal collection and annotation of clinical history, tissue samples, imaging studies, patient reported outcomes, and other pertinent information in participants with these rare tumors and return of results to participants will provide a service to the participants themselves and to the medical community, in line with the NIH mission of to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability .
Objective:
To comprehensively and longitudinally evaluate the natural history of participants with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival).
Eligibility:
Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year).
OR
Relatives of participants with diagnosis of rare solid tumors
OR
Carriers of germline genetic variants that predispose to rare solid tumor and their relatives.
Design:
This will be a long-term study to comprehensively study participants (and their relatives) with select rare tumors.
Initially participants will provide clinical information (medical history, family medical history, imaging studies and reports, surgical pathology reports, genetic test results, patient-reported outcomes) and biospecimens (archival pathology specimen and saliva) for review by and feedback from the study team.
If indicated, participants will be invited to the study site for additional evaluations and consultation, including clinical phenotyping, genotyping, imaging of tumor sites, and patient reported or other appropriate outcomes.
After evaluation, participants will be provided with recommendations about possible treatment options and might be enrolled into disease specific sub-protocols of this trial.
Since long-term follow-up of individuals with rare tumors, their family members at high risk for developing tumors, and carriers of germline genetic variants is a major feature of the study, we intend to maintain active contact with study subjects for as long as possible.
In addition to evaluating individual participants, this protocol will allow bringing groups of participants (approximately 10-20) with specific rare tumors for a rare tumor clinic on the same day to allow for development of a deeper understanding of rare tumors through the conduct of focus groups.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Mary F Wedekind Malone, D.O.
- Telefonnummer: (240) 858-3765
- E-Mail: maryfrances.wedekindmalone@nih.gov
Studieren Sie die Kontaktsicherung
- Name: Barbara J Thomas, R.N.
- Telefonnummer: (240) 858-3633
- E-Mail: barbara.thomas2@nih.gov
Studienorte
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- Rekrutierung
- National Institutes of Health Clinical Center
-
Kontakt:
- National Cancer Institute Referral Office
- Telefonnummer: 888-624-1937
- E-Mail: ncimo_referrals@mail.nih.gov
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Oregon Health and Science University
-
Kontakt:
- Takumi Suzuki
- Telefonnummer: 503-494-3621
- E-Mail: suzukit@ohsu.edu
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Texas Children's Hospital
-
Kontakt:
- Gaylon Stevenson
- Telefonnummer: (713) 798-495_
- E-Mail: gnsteve1@texaschildrens.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Primary clinical
Beschreibung
- INCLUSION CRITERIA:
- Cohort 1: Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year). There are no age restrictions beyond the neonatal period (4 weeks).
OR
-Cohort 2: Participants without a rare tumor who have a germline genetic variant that predisposes to a rare solid tumor
OR
-Cohort 3: Relatives of participants with diagnosis of rare solid tumors who do NOT have a known germline variant that predisposes to a rare solid tumor
OR
- Cohort 4: Parent/guardian of child participating in a focus group if not already enrolled on the study.
- Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
None
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
1/Cohort 1
Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year) |
|
2/Cohort 2
Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor |
|
3/Cohort 3
Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor. |
|
4/ Cohort 4
Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3) |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)
Zeitfenster: 10 years
|
To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival) |
10 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Mary F Wedekind Malone, D.O., National Cancer Institute (NCI)
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 190016
- 19-C-0016
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
IPD-Sharing-Zeitrahmen
Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD-Sharing-Zugriffskriterien
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .